These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 34956861)

  • 1. PARP Inhibition Activates STAT3 in Both Tumor and Immune Cells Underlying Therapy Resistance and Immunosuppression In Ovarian Cancer.
    Martincuks A; Song J; Kohut A; Zhang C; Li YJ; Zhao Q; Mak E; Rodriguez-Rodriguez L; Yu H; Cristea M
    Front Oncol; 2021; 11():724104. PubMed ID: 34956861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer.
    Ding L; Wang Q; Martincuks A; Kearns MJ; Jiang T; Lin Z; Cheng X; Qian C; Xie S; Kim HJ; Launonen IM; Färkkilä A; Roberts TM; Freeman GJ; Liu JF; Konstantinopoulos PA; Matulonis U; Yu H; Zhao JJ
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36609487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation.
    Nguyen LL; Watson ZL; Ortega R; Woodruff ER; Jordan KR; Iwanaga R; Yamamoto TM; Bailey CA; To F; Jeong AD; Guntupalli SR; Behbakht K; Gibaja V; Arnoult N; Cocozaki A; Chuong EB; Bitler BG
    Mol Cancer Ther; 2024 May; ():. PubMed ID: 38714351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation.
    Nguyen LL; Watson ZL; Ortega R; Woodruff ER; Jordan KR; Iwanaga R; Yamamoto TM; Bailey CA; To F; Jeong AD; Guntupalli SR; Behbakht K; Gibaja V; Arnoult N; Cocozaki A; Chuong EB; Bitler BG
    Mol Cancer Ther; 2024 Jun; ():OF1-OF16. PubMed ID: 38863225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of Wnt signaling promotes olaparib resistant ovarian cancer.
    Yamamoto TM; McMellen A; Watson ZL; Aguilera J; Ferguson R; Nurmemmedov E; Thakar T; Moldovan GL; Kim H; Cittelly DM; Joglar AM; Brennecke EP; Wilson H; Behbakht K; Sikora MJ; Bitler BG
    Mol Carcinog; 2019 Oct; 58(10):1770-1782. PubMed ID: 31219654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on poly(ADP-ribose) polymerase inhibitors resistance in ovarian cancer.
    Dong R; Ding T; Li Z
    Front Pharmacol; 2023; 14():1164395. PubMed ID: 37426808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PARP inhibitor resistance: the underlying mechanisms and clinical implications.
    Li H; Liu ZY; Wu N; Chen YC; Cheng Q; Wang J
    Mol Cancer; 2020 Jun; 19(1):107. PubMed ID: 32563252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2
    Liu L; Cai S; Han C; Banerjee A; Wu D; Cui T; Xie G; Zhang J; Zhang X; McLaughlin E; Yin M; Backes FJ; Chakravarti A; Zheng Y; Wang QE
    Mol Cancer Ther; 2020 Jan; 19(1):199-210. PubMed ID: 31534014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.
    Jiao S; Xia W; Yamaguchi H; Wei Y; Chen MK; Hsu JM; Hsu JL; Yu WH; Du Y; Lee HH; Li CW; Chou CK; Lim SO; Chang SS; Litton J; Arun B; Hortobagyi GN; Hung MC
    Clin Cancer Res; 2017 Jul; 23(14):3711-3720. PubMed ID: 28167507
    [No Abstract]   [Full Text] [Related]  

  • 10. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
    Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
    Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
    [No Abstract]   [Full Text] [Related]  

  • 11. EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell-Dependent Manner.
    Nguyen LL; Watson ZL; Ortega R; Woodruff ER; Jordan KR; Iwanaga R; Yamamoto TM; Bailey CA; To F; Lin S; Villagomez FR; Jeong AD; Guntupalli SR; Behbakht K; Gibaja V; Arnoult N; Chuong EB; Bitler BG
    Mol Cancer Res; 2024 Dec; 22(12):1117-1127. PubMed ID: 39136655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic applications of PARP inhibitors in ovarian cancer.
    Xie H; Wang W; Xia B; Jin W; Lou G
    Biomed Pharmacother; 2020 Jul; 127():110204. PubMed ID: 32422564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PARP inhibitors in ovarian cancer: Mechanisms, resistance, and the promise of combination therapy.
    Bhatia T; Doshi G; Godad A
    Pathol Res Pract; 2024 Nov; 263():155617. PubMed ID: 39357181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cells.
    Han Y; Chen MK; Wang HL; Hsu JL; Li CW; Chu YY; Liu CX; Nie L; Chan LC; Yam C; Wang SC; He GJ; Hortobagyi GN; Tan XD; Hung MC
    Am J Cancer Res; 2019; 9(3):608-618. PubMed ID: 30949414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acquired resistance of phosphatase and tensin homolog-deficient cells to poly(ADP-ribose) polymerase inhibitor and Ara-C mediated by 53BP1 loss and SAMHD1 overexpression.
    Wang YT; Yuan B; Chen HD; Xu L; Tian YN; Zhang A; He JX; Miao ZH
    Cancer Sci; 2018 Mar; 109(3):821-831. PubMed ID: 29274141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.
    Hurley RM; Wahner Hendrickson AE; Visscher DW; Ansell P; Harrell MI; Wagner JM; Negron V; Goergen KM; Maurer MJ; Oberg AL; Meng XW; Flatten KS; De Jonge MJA; Van Herpen CD; Gietema JA; Koornstra RHT; Jager A; den Hollander MW; Dudley M; Shepherd SP; Swisher EM; Kaufmann SH
    Gynecol Oncol; 2019 Apr; 153(1):127-134. PubMed ID: 30686551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDC7 Inhibition Potentiates Antitumor Efficacy of PARP Inhibitor in Advanced Ovarian Cancer.
    Liu S; Deng P; Yu Z; Hong JH; Gao J; Huang Y; Xiao R; Yin J; Zeng X; Sun Y; Wang P; Geng R; Chan JY; Guan P; Yu Q; Teh BT; Jiang Q; Xia X; Xiong Y; Chen J; Huo Y; Tan J
    Adv Sci (Weinh); 2024 Oct; ():e2403782. PubMed ID: 39412086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trastuzumab-Resistant HER2
    Wielgos ME; Zhang Z; Rajbhandari R; Cooper TS; Zeng L; Forero A; Esteva FJ; Osborne CK; Schiff R; LoBuglio AF; Nozell SE; Yang ES
    Mol Cancer Ther; 2018 May; 17(5):921-930. PubMed ID: 29592880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitors.
    Lee EK; Matulonis UA
    Expert Opin Emerg Drugs; 2020 Jun; 25(2):165-188. PubMed ID: 32569489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PARP Inhibition Induces Enrichment of DNA Repair-Proficient CD133 and CD117 Positive Ovarian Cancer Stem Cells.
    Bellio C; DiGloria C; Foster R; James K; Konstantinopoulos PA; Growdon WB; Rueda BR
    Mol Cancer Res; 2019 Feb; 17(2):431-445. PubMed ID: 30401718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.